Cannabix Technologies Provides Technology Update on Marijuana Breathalyzer Development
June 18 2018 - 8:45AM
InvestorsHub NewsWire
501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone: (604) 551-7831 Fax: 604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Provides Technology Update
on Marijuana Breathalyzer
Development
The Cannabix Marijuana
Breathalyzer is being developed to give law enforcement and
employers a tool to enforce public safety.
Vancouver, British Columbia
-- June
18, 2018 -- InvestorsHub NewsWire -- Cannabix
Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company or
Cannabix") developer of the Cannabix Marijuana Breathalyzer for law
enforcement and the workplace,
is pleased to report
that recent testing with Beta 3.0 has shown the identification and
first order separation of two key metabolites of
9-tetrahydrocannabinol
("THC"), being
11-hydroxy-delta-9-tetrahydrocannabinol and
11-nor-9-carboxy-tetrahydrocannabinol
in standards. In addition,
scientists have made significant progress towards using lower flow
rates that will become important for user groups with poor
lung function. Furthermore, engineers have been testing
a new breath capture method that
can hold THC breath samples in a stable manner for several
days.
9-tetrahydrocannabinol (“THC”) the main
psychoactive component of marijuana is metabolized into and
11-nor-9-carboxy-tetrahydrocannabinol at different rates based on
route of entry into the body. Smoked THC is converted predominantly
to 11-nor-9-carboxy-tetrahydrocannabinol which is then
glucuronidated to a water-soluble form that can be detected in body
fluids. Ingested THC is metabolized via the hepatic portal
circulation to 11-hydroxy-delta-9-tetrahydrocannabinol prior to
oxidation to 11-nor-9-carboxy-tetrahydrocannabinol. The Cannabix
FAIMS device coupled to real time switchable mass spectrometry is
actively being tuned to detect these key molecules and their
complex pathways in the body to enable the identification of
recency of use.
The recent passing of legislation Bill
C-45 by the Senate of Canada and legislative developments in the
State of Vermont, have increased the number of inquires for the Cannabix
breathalyzer device and the Company has received interest in
piloting from both U.S. and Canadian law enforcement groups as well
as other organizations that drug test their employees. The
Senate Judiciary Committee
in the state of Vermont
recently rejected a bill
to use saliva testing for THC
enforcement, amid concerns of
scientific validity, accuracy, and infringement on civil
liberties.
Rav Mlait, CEO, stated, "With the passing of Bill
C-45 in Canada
the growing problem of drugged driving
will increasingly become an issue of paramount concern for federal,
provincial and civic governmental officials and the public at large
who are concerned about
maintaining public safety on our
roads, institutions and in our workplaces. A recent study
by the Governors Highway Safety Association found that
drugs are being detected more often in drivers
responsible for fatal crashes. The problem
of drugged driving is compounded by lack of
nationally accepted method for testing drugged driver impairment. Cannabix Technologies has been at the forefront of research and
development in this arena and understands the
complexities related to breath testing for marijuana. As the issue
of drugged driving becomes increasingly acute, Cannabix is
committed to using its technology, R&D and scientific
experience to provide effective tools to aid law enforcement and
help governments and the public transition to marijuana
legalization in various jurisdictions."
About Cannabix Technologies Inc.
Cannabix
Technologies Inc. is a leader in marijuana breathalyzer development
for law enforcement and the workplace. Cannabix has established
breath testing technologies in the pursuit of bringing durable,
portable hand-held tools to market to enhance detection of
marijuana impaired driving offences on roads at a time when
marijuana is becoming legal in many global jurisdictions. Cannabix
is working to develop drug-testing devices that will detect THC-
the psychoactive component of marijuana that causes intoxication-
using breath samples. In particular, Cannabix is focused on
developing breath testing devices for detection of recent use of
THC, in contrast to urine testing for THC metabolite that requires
an invasive collection and reflects usage, days or even weeks earlier. The devices will also
be useful for other practical applications such as testing
employees in the workplace where impairment by
THC can be hazardous.
We seek Safe Harbor.
On behalf of the Board
of Directors
"Rav Mlait"
CEO
Cannabix Technologies Inc.
For further information, contact the Company
at info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains
forward-looking information that involves various risks and
uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cannabix Technologies (CSE:BLO)
Historical Stock Chart
From Apr 2023 to Apr 2024